newsfilter
← Latest News
GlobeNewswire·

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results

First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026Nominated KER-206, a novel ligand trap designed to bind select TGF-β ligands to regulate bone